The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if cobitolimod (former called Kappaproct®) is
effective in the treatment of chronic active ulcerative colitis patients not responding to
available therapy.